Stock comparison
Halozyme Therapeutics
Regeneron Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
REGN
Regeneron Pharmaceuticals
Market cap
$65.82B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | REGN | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 64C | HALO |
| Benjamin Graham | 83A | 68B | HALO |
| Philip Fisher | 65B | 48D | HALO |
| Peter Lynch | 53D | 26F | HALO |
| Joel Greenblatt | 40D | 45D | REGN |
| Charlie Munger | 80C | 59C | HALO |
| Terry Smith | 84A | 57C | HALO |
Side-by-side metrics
| Metric | HALO | REGN |
|---|---|---|
| Market cap | $8.1B | $65.82B |
| P/E (TTM) | 24.0x | 16.4x |
| EV/EBIT | 10.2x | 20.0x |
| ROIC (TTM) | 23.65% | 8.53% |
| Gross margin | 81.24% | 84.55% |
| Net margin | 23.13% | 29.65% |
| Revenue CAGR 5y | 33.23% | -2.81% |
| EPS CAGR 5y | -1.98% | -13.35% |
| Debt / Equity | 1.0x | 0.1x |
| Dividend yield | 0.0% | 0.51% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs -2.81%+108%
- EPS CAGR 5y-1.98%vs -13.35%+85%
- ROIC (TTM)23.65%vs 8.53%+64%
- EV/EBIT10.2xvs 20.0x+49%
REGN leads on
- Dividend yield0.51%vs 0.0%+100%
- Debt / Equity0.1xvs 1.0x+91%
- Market cap$65.82Bvs $8.1B+88%
- P/E (TTM)16.4xvs 24.0x+32%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.